Genmab A/S announced DARZALEX sales results for the first quarter of 2024. For the quarter, the company reported net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million. Net trade sales were USD 1,464 million in the U.S. and USD 1,228 million in the rest of the world.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,061 DKK | +5.91% | +5.45% | -4.36% |
May. 03 | GENMAB : A good start to 2024; guidance unchanged | |
May. 03 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.36% | 19.25B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B | |
-24.53% | 8.26B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024